What a way to start 2025!!! I am extremely grateful to the commission that positively evaluated my application. But most of all, thanks thanks thanks to my mentor @prat-aleix-md.bsky.social for believing in me, sometimes even more than myself 😝

Oh, and happy new year from Sicily to you all

For sure, outstanding discussion by prof Harold Burstein from @dfcibreastonc.bsky.social. Here some of his conclusions (and the previous algorithm was his slides as well as the comparison in toxicities and mPFS)

Maybe we can offer some hints at the poster spotlight session 2 tomorrow Dec 12 07:00-08:30 with our preliminary results of TARGET-POST-CDK study, PS2-07 😊
#IsabelGarciaFructuoso @prat-aleix-md.bsky.social @idibaps.bsky.social @hospitalclinic.bsky.social @oncoalert.bsky.social @ub.edu

Also, the toxicity profiles compared to other oral SERD was quite good. This positions the combo as the potential standard II-line for ALL patients progressing to CDK4/6i where the dependency on ER pathway is still there. BUT who are these pts? 👇🏻

BUT, differently from imlune alone, imlune+abema was also superior to imlune in ALL pts, including those without ESR1mut, and after previous I-line CDK4/6inhibitors (mostly palbo/ribo) and in PI3Kpathway-altered BC, with a mPFS that is superior to every ET-based regimen so far

Barcelona!

Una maravilla! Recomendadísimo

@ub.edu @idibaps.bsky.social @hospitalclinic.bsky.social

Finally, a huge thank you to #ESMO and #EvandroDeAzambuja, as without the #Fellowship programme I would have never had the possibility to do this research and probably be where I am now.

I would like to thank all the people involved in this study, but special thanks go to @prat-aleix-md.bsky.social who guided me through and pushed me to move forward, #FaraBrasó for her teachings and suggestions, @tomaspascualmd.bsky.social for giving me THAT database to "play with" in 2019 🙏🏻

More cool stuff can be found in the full publication available in OA at this link 👇 authors.elsevier.com/sd/article/S..., including cell lines experiments and further insights.

It's been several years of my life spent on this project and likely many more to come, following up on this.

In addition, we found out that molecular downstaging or persistence of ROR-P-low or Luminal A subtype from baseline to surgery showed a trend for improved outcomes

We then observed that both NACT and NET promote a molecular downstaging inducing molecular subtype shifting to luminal A or normal-like and to ROR-P-low-risk class

We took into account 3 different response type, i.e. molecular responders (i.e. ROR-low and Ki67 10% after treatment) and pathologic responders. Using multiclass SAM, we revealed differential baseline gene expression differences among responders and non responders to NACT and NET